InnovaVector is a Contract Development and Manufacturing Organization (CDMO) specialising in the design, development, and GMP production of AAV viral vectors for gene therapies. Founded in 2020 as a spin-off from the Telethon Institute of Genetics and Medicine (TIGEM), the company combines innovative approaches with over 20 years of experience to support the development of novel cell and gene therapies.

InnovaVector provides a full range of services from plasmid cloning to GMP production of adeno-associated viral vectors (AAV). The company’s advanced capabilities extend from early discovery research to clinical trial support, addressing the growing demand for gene therapy solutions.

Key Products and Services

• Plasmid cloning and discovery research production
• Process development and technology transfer
• GMP production of AAV viral vectors
• Quality management and regulatory support

InnovaVector is at the forefront of advancing gene therapies, playing a critical role in developing life-changing treatments from research to clinical applications.